← All trials
NCT03369002
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2017
- Primary completion
- May 15, 2018
- Completion date
- May 15, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CymaBay Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.